All filters
Videos
Combination treatment of a TLR7 agonist RO7020531 and a core protein allosteric modulator RO7049389 achieved sustainable viral load suppression and HBsAg loss in an AAV-HBV mouse model | Yonghong Zhu
Presented at:
International Workshop on HBV Cure 2018
Videos
Establishing functional control of HBV and HDV infection with REP 2139-based combination therapy | Andrew Vaillant
Presented at:
International Workshop on HBV Cure 2018
Videos
Clinical update on reducing HBV virus and antigen production using RNAi | Bruce Given
Presented at:
International Workshop on HBV Cure 2018
Videos
Clinical update, antiviral effect and mode of action of capsid assembly modulators | Jeysen Yogaratnam
Presented at:
International Workshop on HBV Cure 2018
Videos
Targeting HBV Core Protein to Clear Infection and Achieve Higher Cure Rates | Richard Colonno
Presented at:
International Workshop on HBV Cure 2018
Videos
Clinical progress of the entry inhibitor Myrcludex B | Stephan Urban
Presented at:
International Workshop on HBV Cure 2018
Videos
Rationale for different Virological Targets in HBV | Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC
Presented at:
International Workshop on HBV Cure 2018
Meeting
European HIV Clinical Forum 2018
Slidesets
Longer duration of virological suppression and a fully active companion drug ensure a high rate of virological control in HIV-1 infected patients switching to a dual therapy containing integrase inhibitors- Daniele Armenia
Presented at:
European HIV Clinical Forum 2018
Slidesets
Integrase inhibitors in specific populations- Women and those aging with HIV- Sharon Walmsley, FRCPC, MD, MSC
Presented at:
European HIV Clinical Forum 2018
Slidesets
Long-acting ARV for treatment & prevention: clinical considerations- Laura Waters, MD, FRCP
Presented at:
European HIV Clinical Forum 2018
Slidesets
Pharmacologic characteristics and delivery options for integrase inhibitors- Courtney Fletcher, PharmD
Presented at:
European HIV Clinical Forum 2018
Slidesets
Intergrase inhibitors- What's new?-Margaret Johnson, MD
Presented at:
European HIV Clinical Forum 2018
Slidesets
Resistance to integrase inhibitors- What clinicians need to know- Roger Paredes, MD, PhD
Presented at:
European HIV Clinical Forum 2018
Slidesets
Reduced drug regimens- What are the data?- Jose Arribas, MD
Presented at:
European HIV Clinical Forum 2018
Slidesets
Switching antiretroviral therapy to safer strategies based on intergrase inhibitors- Pedro Cahn, MD, PhD
Presented at:
European HIV Clinical Forum 2018
Slidesets
CPK/PD Support for a Phase 1 Study of TBA-7371- Jerry Nedelman, PhD
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018
Slidesets
Bedaquiline appears to antagonize its own main metabolite’s QTcF interval prolonging effect- Lénaïg Tanneau, PhD
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018
Slidesets
TPreclinical and Clinical Pharmacokinetics and Pharmacodynamics Analysis of Delamanid- Suresh Mallikaarjun, PHD, FCP
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018
Slidesets
Translational pharmacokinetic modelling & simulation of an experimental long-acting injectable formulation of bedaquiline- An Vermeulen, PhD
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018
Slidesets
Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention- Anthony Podany, PharmD
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018